Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Geron Corp (GERN)

Geron Corp (GERN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 269,445
  • Shares Outstanding, K 188,423
  • Annual Sales, $ 1,070 K
  • Annual Income, $ -27,020 K
  • 60-Month Beta 2.51
  • Price/Sales 263.37
  • Price/Cash Flow N/A
  • Price/Book 1.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.03
  • Growth Rate Est. (year over year) -366.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.29 +10.85%
on 09/26/19
1.55 -7.74%
on 10/11/19
-0.01 (-0.69%)
since 09/18/19
3-Month
1.11 +28.83%
on 08/05/19
1.64 -12.80%
on 09/13/19
+0.18 (+14.40%)
since 07/18/19
52-Week
0.95 +49.74%
on 12/21/18
2.14 -33.18%
on 04/11/19
-0.28 (-16.37%)
since 10/18/18

Most Recent Stories

More News
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of Geron common stock as inducements to three newly-hired employees...

GERN : 1.43 (-4.03%)
Geron Starts Enrollment in Phase III MDS Study on Imetelstat

Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.

JNJ : 127.70 (-6.22%)
XLRN : 42.15 (-2.54%)
CELG : 102.95 (+1.13%)
GERN : 1.43 (-4.03%)
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk...

GERN : 1.43 (-4.03%)
Companies Turn to Advanced Therapies to Curb the Spread of Cancer

FinancialBuzz.com News Commentary

ADXS : 0.35 (+6.71%)
GERN : 1.43 (-4.03%)
SLS : 0.13 (unch)
ONPH : 0.0320 (-17.95%)
Companies Turn to Advanced Therapies to Curb the Spread of Cancer

In 2019, the American Cancer Society projected 1.76 million new cancer cases diagnosed and the number of deaths to stand at 606,880 in the U.S. Overall, the alarming projection has caused concern within...

ONPH : 0.0320 (-17.95%)
KDMN : 2.91 (+3.56%)
ADXS : 0.35 (+6.71%)
SLS : 0.13 (unch)
GERN : 1.43 (-4.03%)
Geron's Imetelstat Gets Fast Track Status for Myelofibrosis

Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.

JNJ : 127.70 (-6.22%)
GERN : 1.43 (-4.03%)
CELG : 102.95 (+1.13%)
XLRN : 42.15 (-2.54%)
Biotechs Endeavour to Increase Access to Cancer Treatments

Cancer is the second leading cause of death globally and was responsible for approximately 9.6 million deaths in 2018, according to the World Health Organization (WHO). Statistically, cancer is the cause...

ONPH : 0.0320 (-17.95%)
AGEN : 2.62 (-2.24%)
INO : 2.25 (-4.66%)
GERN : 1.43 (-4.03%)
ACST : 2.04 (-6.42%)
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis

Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2...

GERN : 1.43 (-4.03%)
Geron to Present at 2019 Cantor Global Healthcare Conference

Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 2019 Cantor Global Healthcare Conference...

GERN : 1.43 (-4.03%)
Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

JNJ : 127.70 (-6.22%)
CELG : 102.95 (+1.13%)
XLRN : 42.15 (-2.54%)
GERN : 1.43 (-4.03%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Trade GERN with:

Business Summary

Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking...

See More

Key Turning Points

2nd Resistance Point 1.53
1st Resistance Point 1.48
Last Price 1.43
1st Support Level 1.40
2nd Support Level 1.37

See More

52-Week High 2.14
Fibonacci 61.8% 1.69
Fibonacci 50% 1.55
Last Price 1.43
Fibonacci 38.2% 1.41
52-Week Low 0.95

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar